์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

MABT388

Anti-ADAM 17 Antibody, clone 16C11.1 | MABT388

clone 16C11.1, from mouse

๋™์˜์–ด(๋“ค):

Disintegrin and metalloproteinase domain-containing protein 17, ADAM 17, Snake venom-like protease, TNF-alpha convertase, TNF-alpha-converting enzyme, CD156b

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ

๋ณด๊ธฐ ๋ณ€๊ฒฝ

์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
16C11.1, monoclonal
Application:
IHC, WB
Citations:
-
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜


biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

16C11.1, monoclonal

species reactivity

human

technique(s)

immunohistochemistry: suitable (paraffin), western blot: suitable

isotype

IgG1κ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... ADAM17(6868)

General description

Disintegrin and metalloproteinase domain-containing protein 17 (EC 3.4.24.86; UniProt P78536; also known as ADAM 17, CD156b, Snake venom-like protease. TNF-alpha convertase, TNF-alpha-converting enzyme, Tumor necrosis factor alpha-converting enzyme) is encoded by the ADAM17 (also known as CD156B, CSVP, NISBD, NISBD1, TACE) gene (Gene ID 6868) in human. Originally described as a TNFโ€“alpha converting enzyme, ADAM17 is known to process the cleavage of many transmembrane proteins, including membrane-anchored cytokines, cell adhesion molecules, receptors, ligands, and enzymes. ADAM17 was the first โ€ฒsheddaseโ€ฒ identified. ADAM17 activity is regulated by multiple post-translational modifications. It has three phosphorylation sites on its C-terminal cytoplasmic domain (T735, S791, and (S819). ERK1/2-mediated T735 phosphorylation is reported to regulate ADAM17 maturation and surface expression. ADAM 17 is initially translated in its prepro-form and subsequent cleavages of the signal (aa 1-17) and propeptide (18-214) sequences produces the 610 aa mature ADAM 17 (aa 215-824).
~120 kDa observed. A lower band ~100 kDa is also observed when using a higher antibody concentration (5 ยตg/mL). Due to glycosylation, target band size appears larger than the calculated molecular weights (93.0 kDa/prepro-isoform A, 68.2 kDa/mature isoform A, 78.5kDa/prepro-isoform B, 63.7 kDa/mature isoform B). Uncharacterized band(s) may appear in some lysates.

Immunogen

GST-tagged recombinant protein corresponding to human ADAM 17.

Application

Research Category
Cell Structure
Research Sub Category
Adhesion (CAMs)
This mouse Monoclonal Anti-ADAM 17 Antibody, clone 16C11.1, Cat. No. MABT388 detects levels of ADAM17, and has been published and validated for use in Western Blotting, Immunohistochemistry (Paraffin).
Western Blotting Analysis: 5.0 ยตg/mL from a representative lot detected ADAM 17 in 10 ยตg of human acute myelogenous leukemia KG-1 cell lysate.
Immunohistochemistry Analysis: A 1:50-250 dilution from a representative lot detected ADAM 17 in human testis and colorectal cancer tissues.

Biochem/physiol Actions

Expected to react with both spliced isoforms.

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1ฮบ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Preparation Note

Stable for 1 year at 2-8ยฐC from date of receipt.

Analysis Note

Evaluated by Western Blotting in human acute myelogenous leukemia KG-1 cell lysate.

Western Blotting Analysis: 0.5 ยตg/mL of this antibody detected ADAM 17 in 10 ยตg of human acute myelogenous leukemia KG-1 cell lysate.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

์ œํ’ˆ ์„ ํƒ ๋„๊ตฌ}๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ์„ ํƒ์˜ ํญ์„ ์ขํ˜€๋ณด์„ธ์š”.


์ €์žฅ ๋“ฑ๊ธ‰

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



์‹œํ—˜ ์„ฑ์ ์„œ(COA)

์ œํ’ˆ์˜ ๋กœํŠธ/๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋ฅผ ์ž…๋ ฅํ•˜์—ฌ ์‹œํ—˜ ์„ฑ์ ์„œ(COA)์„ ๊ฒ€์ƒ‰ํ•˜์‹ญ์‹œ์˜ค. ๋กœํŠธ ๋ฐ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋Š” ์ œํ’ˆ ๋ผ๋ฒจ์— ์žˆ๋Š” โ€˜๋กœํŠธโ€™ ๋˜๋Š” โ€˜๋ฐฐ์น˜โ€™๋ผ๋Š” ์šฉ์–ด ๋’ค์—์„œ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ


๊ด€๋ จ ์ฝ˜ํ…์ธ 

A major focus of breast cancer research is to understand the mechanisms responsible for disease progression and drug resistance. Toward that end, it has been found that approximately two thirds of all human breast carcinomas overexpress the Estrogen Receptor ฮฑ (ERฮฑ) protein and it remains the primary pharmacological target for endocrine therapy1,2. The normal cellular function of ERฮฑ is as a transcription factor that mediates a wide variety of physiological processes, many of which are dependent upon phosphorylation of the receptor at specific amino acid residues3,4. Indeed, ERฮฑ is known to be phosphorylated at a multitude of different sites, yet how these all correlate to disease remains unclear5. Here, we interrogated multiple sites of ERฮฑ for phosphorylation status by screening an extensive panel of different breast cancer patient samples and other non-breast cancer tissue microarray (TMA) slide samples to determine their relevance to disease.





๊ตญ์ œ ๋ฌด์—ญ ํ’ˆ๋ชฉ ๋ฒˆํ˜ธ

SKUGTIN
MABT38804055977176506